Review

Nature Reviews Cancer 5, 436-446 (June 2005) | doi:10.1038/nrc1627

Tumour vascular targeting

Dario Neri1 & Roy Bicknell2  About the authors

Top

It is now accepted that the growth of solid tumours is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process. More recently, it has become apparent that targeted destruction of the established tumour vasculature is another avenue for exciting therapeutic opportunities. In this article, we present evidence that vascular targeting is an effective antitumour strategy in animal models, describe strategies for identifying putative tumour vascular targets and discuss future prospects for vascular targeting in the clinic.

Author affiliations

  1. Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zürich, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland.
  2. Angiogenesis Laboratory, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, Radcliffe Hospital, Oxford OX3 9DS, UK.

Correspondence to: Roy Bicknell2 Email: Roy.Bicknell@cancer.org.uk

Correspondence to: Dario Neri1 Email: dario.neri@pharma.ethz.ch